Literature DB >> 18987883

Transient myelofibrosis with autoimmune pancytopenia: a case report.

Tomohei Nakao1, Takashi Fukushima, Takashi Shimizu, Toru Nanmoku, Satoshi Fujiyama, Ryoko Nakajima, Fujiko Fukushima, Masayuki Noguchi, Ryo Sumazaki.   

Abstract

INTRODUCTION: Myelofibrosis associated with myelodysplasia is thought to herald poor prognosis in myelodysplastic syndrome (MDS). CASE REPORT: A 7-month-old boy presented with fever (39 degrees C), pancytopenia, and slight hepatosplenomegaly (3 and 2 cm, respectively). Bone marrow showed hypercellularity, hyperplasia of erythroblasts, and also myelofibrosis. IgG was 1,136 mg/dL, IgA was 131 mg/dL, and IgM was 89 mg/dL. Antinuclear and antineutrophil antibodies, red-blood-cell-associated IgG, antiplatelet antibodies, and Coombs test were positive. Karyotype was 46XY. No viral cause was evidenced. Mild myelodysplasia was revealed two months later, but was insufficient to support a diagnosis of MDS. The boy was treated with transfusion of packed cells, prednisolone 2 mg/kg/day for 3 weeks associated with intravenous gammaglobulin 400 mg/kg/day for 5 days. Direct Coombs remained positive 1 month after treatment for 5 months, myelofibrosis persisted for 3 months, and neutropenia for 21 months. After 3-year follow-up, hematological data were normal without any therapeutic intervention.
CONCLUSION: Myelofibrosis associated with mild myelodysplasia and pancytopenia can have a benign evolution in infants and young children.

Entities:  

Mesh:

Year:  2008        PMID: 18987883     DOI: 10.1007/s00431-008-0867-y

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  26 in total

1.  The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.

Authors:  H Tamaki; H Ogawa; K Ohyashiki; J H Ohyashiki; H Iwama; K Inoue; T Soma; Y Oka; T Tatekawa; Y Oji; A Tsuboi; E H Kim; M Kawakami; K Fuchigami; M Tomonaga; K Toyama; K Aozasa; T Kishimoto; H Sugiyama
Journal:  Leukemia       Date:  1999-03       Impact factor: 11.528

2.  Autoimmune hemolytic anemia occurring with myelodysplastic syndrome: report of a pediatric case and review of the literature.

Authors:  H Oren; C Uçar; H Gülen; M Duman; G Irken
Journal:  Ann Hematol       Date:  2001-09       Impact factor: 3.673

3.  Myelofibrosis in primary myelodysplastic syndromes: a retrospective study of 352 patients.

Authors:  H Maschek; A Georgii; V Kaloutsi; M Werner; K Bandecar; M G Kressel; H Choritz; M Freund; D Hufnagl
Journal:  Eur J Haematol       Date:  1992-04       Impact factor: 2.997

4.  Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes.

Authors:  R J Sokol; S Hewitt; D J Booker
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

5.  Pancytopenia with myelofibrosis. An unusual presentation of childhood Hodgkin's disease.

Authors:  W L Carroll; F R Berberich; B E Glader
Journal:  Clin Pediatr (Phila)       Date:  1986-02       Impact factor: 1.168

6.  Myelofibrosis-myeloid metaplasia in childhood.

Authors:  L A Boxer; B M Camitta; W Berenberg; J P Fanning
Journal:  Pediatrics       Date:  1975-06       Impact factor: 7.124

7.  [Myelofibrosis regressing under corticotherapy and intravenous immunoglobulins in an infant].

Authors:  H Pilorget; A Bangui; M Adam; G Leverger
Journal:  Arch Pediatr       Date:  1996-01       Impact factor: 1.180

8.  Low incidence of specific anti-platelet antibodies detected by the MAIPA assay in the serum of thrombocytopenic MDS patients and lack of correlation between platelet autoantibodies, platelet lifespan and response to danazol therapy.

Authors:  M Hebbar; C Kaplan; M T Caulier; E Wattel; P Morel; M Wetterwald; F Bauters; P Fenaux
Journal:  Br J Haematol       Date:  1996-07       Impact factor: 6.998

9.  Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients.

Authors:  S Luna-Fineman; K M Shannon; S K Atwater; J Davis; M Masterson; J Ortega; J Sanders; P Steinherz; V Weinberg; B J Lange
Journal:  Blood       Date:  1999-01-15       Impact factor: 22.113

10.  Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1.

Authors:  Anthony Meager; Kumuthini Visvalingam; Pärt Peterson; Kaidi Möll; Astrid Murumägi; Kai Krohn; Petra Eskelin; Jaakko Perheentupa; Eystein Husebye; Yoshihisa Kadota; Nick Willcox
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.